BioNTech SE Quick Ratio 2019-2024 | BNTX

BioNTech SE quick ratio for the quarter ending September 30, 2024 was 7.21.

  • BioNTech SE average quick ratio for 2023 was 10.6, a 87.94% decline from 2022.
  • BioNTech SE average quick ratio for 2022 was 5.64, a 88% increase from 2021.
  • BioNTech SE average quick ratio for 2021 was 3, a 7.69% increase from 2020.

Quick ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated by subtracting inventory from current assets and dividing by current liabilities.

BioNTech SE Quick Ratio 2019-2024 | BNTX

  • BioNTech SE average quick ratio for 2023 was 10.6, a 87.94% decline from 2022.
  • BioNTech SE average quick ratio for 2022 was 5.64, a 88% increase from 2021.
  • BioNTech SE average quick ratio for 2021 was 3, a 7.69% increase from 2020.

Quick ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated by subtracting inventory from current assets and dividing by current liabilities.
Related Stocks
Company NameMarket
Cap
Amgen (AMGN)$158.3B
Bristol Myers Squibb (BMY)$119.4B
Vertex Pharmaceuticals (VRTX)$116.1B
Gilead Sciences (GILD)$112.4B
CSL (CSLLY)$87.2B
Regeneron Pharmaceuticals (REGN)$81.1B
GSK (GSK)$70.4B
Argenex SE (ARGX)$36.2B
Alnylam Pharmaceuticals (ALNY)$31.6B
Biogen (BIIB)$23B
Illumina (ILMN)$22.2B
BeiGene (BGNE)$18.6B
Moderna (MRNA)$15.8B
Incyte (INCY)$13.8B
Genmab (GMAB)$13.7B
Insmed (INSM)$13.1B
BioMarin Pharmaceutical (BMRN)$12.2B
Bio-Techne Corp (TECH)$11.3B
Vaxcyte (PCVX)$11B
Sarepta Therapeutics (SRPT)$10.9B
Exelixis (EXEL)$10.2B
Exact Sciences (EXAS)$9.8B
QIAGEN (QGEN)$9.8B
Revolution Medicines (RVMD)$9.5B
Bio-Rad Laboratories (BIO.B)$9.4B
Roivant Sciences (ROIV)$9.3B
Intra-Cellular Therapies (ITCI)$9.1B
Repligen (RGEN)$8B
Ascendis Pharma (ASND)$7.9B
Legend Biotech (LEGN)$7.5B